Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb dose-finding trial of MK-8237 sublingual house dust mite tablet in adult subjects with house dust mite allergic rhinitis/rhinoconjunctivitis
2012-001855-38Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2012
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and house dust mite allergy comparing MK-8237 dose-finding arm(s) with Placebo (2 arms). Primary endpoint: Average total nasal symptom score during chamber session at Week 24. Started Jul 2012; status: completed.
02
Drugs
House dust mite allergen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)house dust mite allergy
Beyond the preview
Go deeper on 2012-001855-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001855-38.